SAN FRANCISCO and SAN DIEGO, Jan. 5, 2018 /PRNewswire/ -- IDEAYA Biosciences, an oncology-focusedbiotechnology company committed to the discovery of breakthrough small-molecule synthetic lethality and immuno-oncology therapies, today announced that Yujiro S. Hata, chief executive officer of IDEAYA, will present at the 36th Annual J.P. Morgan Healthcare
About IDEAYA Biosciences
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and for enhancing immunotherapy response, and immuno-oncology therapies targeting the tumor micro-environment. IDEAYA, located in South San Francisco and San Diego, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology and small molecule drug discovery. For more information, please visit www.ideayabio.com.
View original content:http://www.prnewswire.com/news-releases/ideaya-biosciences-to-present-at-the-36th-annual-jp-morgan-healthcare-conference-300578037.html
SOURCE IDEAYA Biosciences, Inc.
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All